Disease activity return after natalizumab cessation in multiple sclerosis

References

• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. PubMed PMID: 16510744. doi:10.1056/NEJMoa044397.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–923. PubMed PMID: 16510745. doi:10.1056/NEJMoa044396.
   PubMed Web of Science ®Google Scholar
• Kolasa M, Hagman S, Verkkoniemi-Ahola A, Anti-JC virus seroprevalence in a Finnish MS cohort. Acta Neurol Scand. 2015. PubMed PMID: 26347001. doi:10.1111/ane.12475.
   PubMedGoogle Scholar
• Olsson T, Achiron A, Alfredsson L, et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler. 2013;19(11):1533–1538. PubMed PMID: 23459571. doi:10.1177/1352458513477925.
   PubMed Web of Science ®Google Scholar
• Dorries K. Molecular biology and pathogenesis of human polyomavirus infections. Dev Biol Stand. 1998;94. PubMed PMID: 9776228. 71–79.
   PubMedGoogle Scholar
• Antonsson A, Green AC, Mallitt KA, et al. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol. 2010;91(Pt 7):1849–1853. PubMed PMID: 20219899. doi:10.1099/vir.0.020115-0.
   PubMed Web of Science ®Google Scholar
• Beltrami S, Gordon J. Immune surveillance and response to JC virus infection and PML. J Neurovirol. 2014;20(2):137–149. PubMed PMID: 24297501; PubMed Central PMCID: PMC3972311. doi:10.1007/s13365-013-0222-6.
   PubMed Web of Science ®Google Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–1880. PubMed PMID: 22591293. doi:10.1056/NEJMoa1107829.
   PubMed Web of Science ®Google Scholar
• Derfuss T, Kappos L. Predicting PML in natalizumab-treated patients: can we do better?. J Neurol Neurosurg Psychiatry. 2013;84(11):1182–1183. PubMed PMID: 23606737. doi:10.1136/jnnp-2012-304777.
   PubMed Web of Science ®Google Scholar
• Derfuss T, Kuhle J, Lindberg R, et al. Natalizumab therapy for multiple sclerosis. Semin Neurol. 2013;33(1):26–36. PubMed PMID: 23709210. doi:10.1055/s-0033-1343793.
   PubMed Web of Science ®Google Scholar
• Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958–963. PubMed PMID: 21613333. doi:10.1177/1352458511401944.
   PubMed Web of Science ®Google Scholar
• Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Sclerosis. 2013;19(5):593–600. PubMed PMID: 22992450. doi:10.1177/1352458512460604.
   PubMed Web of Science ®Google Scholar
• Sangalli F, Moiola L, Bucello S, et al. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci. 2011;31 Suppl 3: 299–302. PubMed PMID: 20544247. doi:10.1007/s10072-010-0344-z
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69(14):1391–1403. PubMed PMID: 17761550. doi:10.1212/01.wnl.0000277457.17420.b5.
   PubMed Web of Science ®Google Scholar
• Vellinga MM, Castelijns JA, Barkhof F, et al. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008;70(13 Pt 2):1150–1151. PubMed PMID: 17872364. doi:10.1212/01.wnl.0000265393.03231.e5.
   PubMed Web of Science ®Google Scholar
• Killestein J, Vennegoor A, Strijbis EM, et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol. 2010;68(3):392–395. PubMed PMID: 20661928. doi:10.1002/ana.22074.
   PubMed Web of Science ®Google Scholar
• Lenhard T, Biller A, Mueller W, et al. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?. Neurology. 2010;75(9):831–833. PubMed PMID: 20805529. doi:10.1212/WNL.0b013e3181f07362.
   PubMed Web of Science ®Google Scholar
• Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011;68(2):186–191. PubMed PMID: 20937940. doi:10.1001/archneurol.2010.257.
   PubMedGoogle Scholar
• West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting?. Ann Neurol. 2010;68(3):395–399. PubMed PMID: 20818793. doi:10.1002/ana.22163.
   PubMed Web of Science ®Google Scholar
• Rigau V, Mania A, Befort P, et al. Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology. 2012;79(22):2214–2216. PubMed PMID: 23100404. doi:10.1212/WNL.0b013e318275979d.
   PubMed Web of Science ®Google Scholar
• Stuve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009;72(5):396–401. PubMed PMID: 18987352; PubMed Central PMCID: PMC2677530. doi:10.1212/01.wnl.0000327341.89587.76.
   Google Scholar
• O’Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858–1865. PubMed PMID: 21543733. doi:10.1212/WNL.0b013e31821e7c8a.
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15–23. PubMed PMID: 12510038. doi:10.1056/NEJMoa020696.
   PubMed Web of Science ®Google Scholar
• Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci. 2011;308(1–2):98–102. PubMed PMID: 21665227. doi:10.1016/j.jns.2011.05.043.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Koch-Henriksen N, Petersen T, et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol. 2014;261(6):1170–1177. PubMed PMID: 24728334. doi:10.1007/s00415-014-7325-8.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Hagemeier J, Kavak KS, et al. Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. J Neurol Neurosurg Psychiatry. 2016. PubMed PMID: 26780938. doi:10.1136/jnnp-2015-312221.
   Google Scholar
• Rossi S, Motta C, Studer V, et al. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol. 2013;20(1):87–94. PubMed PMID: 22741530. doi:10.1111/j.1468-1331.2012.03794.x.
   PubMed Web of Science ®Google Scholar
• Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol. 2011;258(9):1665–1669. PubMed PMID: 21431380. doi:10.1007/s00415-011-5996-y.
   PubMed Web of Science ®Google Scholar
• Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72(5):402–409. PubMed PMID: 19188571; PubMed Central PMCID: PMC2677532. doi:10.1212/01.wnl.0000341766.59028.9d.
   PubMed Web of Science ®Google Scholar
• Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59(5):743–747. PubMed PMID: 16634029. doi:10.1002/ana.20858.
   PubMed Web of Science ®Google Scholar
• Magraner MJ, Coret F, Navarre A, et al. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol. 2011;258(10):1805–1811. PubMed PMID: 21625938. doi:10.1007/s00415-011-6019-8.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Cree BA, De Seze J, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014;82(17):1491–1498. PubMed PMID: 24682966; PubMed Central PMCID: PMC4011468. doi:10.1212/WNL.0000000000000355.
   PubMed Web of Science ®Google Scholar
• Gobbi C, Meier DS, Cotton F, et al. Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol. 2013;13:101. PubMed PMID: 23915113; PubMed Central PMCID: PMC3750382. doi:10.1186/1471-2377-13-101.
   PubMed Web of Science ®Google Scholar
• Kaufman MD, Lee R, Norton HJ. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. Mult Scler. 2011;17(4):490–494. PubMed PMID: 21135017. doi:10.1177/1352458510389103.
   PubMed Web of Science ®Google Scholar
• Havla J, Tackenberg B, Hellwig K, et al. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol. 2013;260(5):1382–1387. PubMed PMID: 23266894. doi:10.1007/s00415-012-6808-8.
   PubMed Web of Science ®Google Scholar
• Clerico M, Schiavetti I, De Mercanti SF, et al. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study). JAMA Neurol. 2014;71(8):954–960. PubMed PMID: 24977406. doi:10.1001/jamaneurol.2014.1200.
   PubMed Web of Science ®Google Scholar
• Salhofer-Polanyi S, Baumgartner A, Kraus J, et al. What to expect after natalizumab cessation in a real-life setting. Acta Neurol Scand. 2014;130(2):97–102. PubMed PMID: 24720783. doi:10.1111/ane.12250.
   PubMed Web of Science ®Google Scholar
• Kivisakk P, Healy BC, Viglietta V, et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009;72(22):1922–1930. PubMed PMID: 19487650; PubMed Central PMCID: PMC2690969. doi:10.1212/WNL.0b013e3181a8266f.
   PubMed Web of Science ®Google Scholar
• Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(9):806–812. PubMed PMID: 19255407; PubMed Central PMCID: PMC2821836. doi:10.1212/01.wnl.0000343880.13764.69.
   PubMed Web of Science ®Google Scholar
• Kaufman M, Cree BA, De Seze J, et al. Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. J Neurol. 2015;262(2):326–336. PubMed PMID: 25381458. doi:10.1007/s00415-014-7558-6.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415. PubMed PMID: 20089954. doi:10.1056/NEJMoa0907839.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. PubMed PMID: 20089952. doi:10.1056/NEJMoa0909494.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, Comi G, et al. Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS. Neurology. 2015;85(1):29–39. PubMed PMID: 26024899; PubMed Central PMCID: PMC4501941. doi:10.1212/WNL.0000000000001706.
   PubMed Web of Science ®Google Scholar
• Cohen M, Maillart E, Tourbah A, et al. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol. 2014;71(4):436–441. PubMed PMID: 24566807. doi:10.1001/jamaneurol.2013.6240.
   PubMed Web of Science ®Google Scholar
• Iaffaldano P, Lucisano G, Pozzilli C, et al. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain. 2015;138(Pt 11):3275–3286. PubMed PMID: 26362907. doi:10.1093/brain/awv260.
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol. 2008;63(3):395–400. PubMed PMID: 18383069. doi:10.1002/ana.21363.
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–688. PubMed PMID: 18272891. doi:10.1056/NEJMoa0706383.
   PubMed Web of Science ®Google Scholar
• Re M L, Capobianco M, Ragonese P, et al. Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (ms): a retrospective study from two Italian MS centers. Neurol Ther. 2015;4(2):147–157. PubMed PMID: 26647006; PubMed Central PMCID: PMC4685862. doi:10.1007/s40120-015-0038-9.
   PubMedGoogle Scholar
• Alping P, Islam-Jakobsson P, Novakova L, et al. Superior efficacy and tolerability of rituximab as compared to fingolimod for MS patients switching from natalizumab due to positive JC virus serology. ectrims 2015. Barcelona: ectrims Online Library; 2015.
   Google Scholar
• Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-term relapse. Neurology. 2014;82(14):1204–1211. PubMed PMID: 24610329; PubMed Central PMCID: PMC4001200. doi:10.1212/WNL.0000000000000283.
   PubMed Web of Science ®Google Scholar
• Rinaldi F, Seppi D, Calabrese M, et al. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler. 2012;18(11):1640–1643. PubMed PMID: 23100526. doi:10.1177/1352458512464282.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Annovazzi P, Capobianco M, et al. Natalizumab discontinuation in patients with multiple sclerosis: profiling risk and benefits at therapeutic crossroads. Mult Scler. 2015;21(13):1713–1722. PubMed PMID: 25698174. doi:10.1177/1352458515570768.
   PubMed Web of Science ®Google Scholar
• Sangalli F, Moiola L, Ferre L, et al. Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients. Mult Scler Relat Disord. 2014;3(4):520–526. PubMed PMID: 25877065. doi:10.1016/j.msard.2014.04.003.
   PubMed Web of Science ®Google Scholar
• Capobianco M, Di Sapio A, Malentacchi M, et al. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation. Eur J Neurol. 2015;22(3):585–587. PubMed PMID: 24995482. doi:10.1111/ene.12487.
   PubMed Web of Science ®Google Scholar
• Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891–895. PubMed PMID: 24821217. doi:10.1001/jamaneurol.2014.209.
   PubMed Web of Science ®Google Scholar
• Ebrahimi N, Herbstritt S, Gold R, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler. 2015;21(2):198–205. PubMed PMID: 25159275. doi:10.1177/1352458514546790.
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247–256. PubMed PMID: 24461574. doi:10.1016/S1474-4422(13)70308-9.
   PubMed Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Sclerosis. 2014;20(6):705–716. PubMed PMID: 24126064. doi:10.1177/1352458513507821.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–1097. PubMed PMID: 22992072. doi:10.1056/NEJMoa1206328.
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–1107. PubMed PMID: 22992073. doi:10.1056/NEJMoa1114287.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819–1828. PubMed PMID: 23122652. doi:10.1016/S0140-6736(12)61769-3.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–1839. PubMed PMID: 23122650. doi:10.1016/S0140-6736(12)61768-1.
   PubMed Web of Science ®Google Scholar
• Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373(15):1418–1428. PubMed PMID: 26444729. doi:10.1056/NEJMoa1501481.
   PubMed Web of Science ®Google Scholar
• Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9884):2167–2175. PubMed PMID: 23562009. doi:10.1016/S0140-6736(12)62190-4.
   PubMed Web of Science ®Google Scholar
• Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779–1787. PubMed PMID: 22047971. doi:10.1016/S0140-6736(11)61649-8.
   PubMed Web of Science ®Google Scholar